CLIA Insulin

Insulin is a key hormone responsible for regulating glucose metabolism. Its measurement provides important information about pancreatic secretion, insulin resistance, and the overall metabolic status of the patient.

Measurement of insulin levels is not routinely used for the primary diagnosis of diabetes. Its main benefit lies in the assessment of specific conditions, such as hyperinsulinemia, insulin resistance, suspected insulinoma, or unexplained hypoglycemia.

For a more comprehensive assessment of beta cell function and differential diagnosis of various forms of diabetes, insulin measurement can be beneficial in combination with C-peptide, which as a more reliable marker is not affected by the administration of exogenous insulin.

The portfolio of markers for functional pancreatic assessment, C-peptide and Insulin, complemented by autoimmune diabetes markers GAD65 and IA-2, which are not commonly available on other CLIA platforms, represents a significant advantage of the CLIA solution from BioVendor Group.

Benefits of BioVendor Group's Diabetes Panel on the CLIA Platform

• The combination of functional and autoimmune markers enables more precise differentiation of type 1 diabetes, LADA, and type 2 diabetes
• Supports early diagnosis of autoimmune diabetes, including in patients with an atypical disease course or unclear classification
• Increases clinical value in situations where standard classification is insufficient and contributes to a better understanding of disease etiology
• Streamlines the testing process and simplifies the interpretation of results
• GAD65 and IA-2 markers in CLIA format on a fully automated platform ensure a high level of automation and maximum user convenience